Skip to content

Advertisement

  • Oral presentation
  • Open Access

Cytokines, chemokines and leukotrienes profile and signature analysis in HTLV-1 infection as an evidence of disease progression

  • 1,
  • 1Email author,
  • 2,
  • 2,
  • 1,
  • 1,
  • 1,
  • 3,
  • 4,
  • 2,
  • 2,
  • 1,
  • 3 and
  • 5
Retrovirology201411 (Suppl 1) :O37

https://doi.org/10.1186/1742-4690-11-S1-O37

  • Published:

Keywords

  • Infectious Disease
  • Negative Correlation
  • Serum Sample
  • Signature Analysis
  • Prognostic Marker

Background

A cross-sectional study evaluated the cytokines, chemokines and leukotrienes profiles as possible biomarkers of progression to HTLV-1 associated myelopathy (HAM).

Methods

Serum samples from 21 healthy blood donors (HBD), 27 asymptomatic carriers (ASC), 32 possible HAM (pHAM) and 28 HAM individuals were tested for cytokines (IL-6, IFN-γ, TNF-α, IL-2, IL-4 and IL-10), chemokines ( RANTES, MCP1, IL-8, MIG and IP-10) and leukotrienes (CysLTs and LTB-4). For each molecule tested, the HTLV-1 individuals were classified as low or high-producers taking the global median index of the HBD group as a cut off.

Results

When comparing AS and pHAM individuals, AS were high-producers of IP-10 and low-producers of RANTES; pHAM were high-producers of IL-2 and low of IL-8. Besides, AS individuals presented a strong positive correlation between the regulatory cytokines IL-10 with IL-4 and between both with the pro-inflammatory cytokines IL-2 and IL-6; a negative correlation was found between RANTES and IL-2. HAM were high-producers of IL-6, IFN-γ, IP-10, LTB4, IL-4, MIG, IL-10, IL-2, presented a positive correlation of TNF-α and IFN-γ with IL-6, but this group had a positive correlation of CysLT with IL-10, IL-4 and TNF-α, contrasting with other groups.

Discussion

HAM displayed a unique signature of inflammation, which was strengthened by CysLT and not counterbalanced by IL-4 and IL-10. This signature was observed in pHAM to a lower extent, becoming more evident in HAM. This profile may indicate disease progression and may serve as prognostic markers in future studies.

Authors’ Affiliations

(1)
Curso de Pós-Graduação em Infectologia e Medicina Tropical, Faculdade de Medicina da Universidade Federal de Minas Gerais - Belo Horizonte, Minas Gerais, Brazil
(2)
Laboratório de Biomarcadores de Diagnóstico e Monitoração, Centro de Pesquisa René Rachou, FIOCRUZ-Minas, Belo Horizonte, Minas Gerais, Brazil
(3)
Fundação Centro de Hematologia e Hemoterapia de Minas Gerais, HEMOMINAS, Minas Gerais, Brazil
(4)
Hospital Sarah Kubitschek, Belo Horizonte, Minas Gerais, Brazil
(5)
Faculdade de Farmácia da USP, Ribeirão Preto, São Paulo, Brazil

Copyright

© Starling et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement